概述
-
货号
DHD37502
-
描述
Lintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225 Ac]Ac-lintuzumab clinical trials were discussed in detail in reference . Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
-
表达系统
Mammalian Cells -
种属反应性
Human -
宿主
Humanized -
同种型
IgG1-kappa -
克隆类型
Monoclonal -
靶标
Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3 -
浓度
1.39 mg/ml -
内毒素水平
Please contact with the lab for this information. -
纯度
>95% as determined by SDS-PAGE. -
纯化方式
Protein A/G purified from cell culture supernatant. -
Accession号
P20138 -
克隆号
Lintuzumab
-
应用
Research Grade Biosimilar -
状态
Liquid -
保存溶液
0.01M PBS, pH 7.4. -
稳定性和存储
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. -
别名
225Ac-lintuzumab, HuM195, SGN-33, SMART M195, HuM195, CAS: 166089-32-3
图片
参考文献
评价
